<DOC>
	<DOCNO>NCT01707394</DOCNO>
	<brief_summary>CV185118 single dose Apixaban PK/PD study pediatric subject . The objective study primarily study PK/PD Apixaban pediatric subject risk thrombosis</brief_summary>
	<brief_title>Study Evaluate Single Dose Apixaban Pediatric Subjects Risk Thrombotic Disorder</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects stable disease risk venous arterial thrombotic disorder Neonates ( ≥ 34 week gestation birth ≥ 37 week post conceptual age ) &lt; 18 year age Subjects functional CVAD ( Central Venous Access Device ) upper low venous system Current recent ( within 3 month study drug administration ) gastrointestinal disease gastrointestinal surgery , opinion investigator BMS Medical Monitor , could impact absorption study drug Active bleeding high risk bleed Inability tolerate oral medication administration oral medication via enteral tube ( nasogastric tube [ NG tube ] gastronomy tube [ Gtube ] )</criteria>
	<gender>All</gender>
	<minimum_age>37 Weeks</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>